Sun to take Taro private after sweetened buy-out offer
This article was originally published in Scrip
Executive Summary
India's Sun Pharmaceutical Industries is set to take Taro Pharmaceutical Industries private after a sweetened offer of $39.50 per share to acquire the remaining 34% not held by Sun in Taro was blessed by the Israeli firm's board. Sun expects to delist Taro from the New York Stock Exchange once the current proposal is executed.